✦ LIBER ✦

Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: A pilot study

✍ Scribed by Shinji Urakami; Tateki Yoshino; Nobuyuki Kikuno; Shin Imai; Satoshi Honda; Tatuaki Yoneda; Hirofumi Kishi; Kazushi Shigeno; Hiroaki Shiina; Mikio Igawa

Book ID: 116944724
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 107 KB
Volume: 65
Category: Article
ISSN: 0090-4295
DOI: 10.1016/j.urology.2004.10.033

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical outcome of patients with doceta

Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy

✍ Thomas Nelius; Tobias Klatte; Werner de Riese; Allan Haynes; Stephanie Filleur 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 201 KB

Biweekly Doxorubicin/Ketoconazole as Sec

Biweekly Doxorubicin/Ketoconazole as Second-Line Treatment in Docetaxel-Resistant, Hormone-Refractory Prostate Cancer

✍ George Lainakis; Antoniou Nikos; Alivizatos Gerassimos; Chrisofos Michael; Mitso 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 80 KB

Response to docetaxel/carboplatin-based

Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer

✍ Mari Nakabayashi; Oliver Sartor; Susanna Jacobus; Meredith M. Regan; David McKea 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

Significance of docetaxel-based chemothe

Significance of docetaxel-based chemotherapy as treatment for metastatic castration-resistant prostate cancer in Japanese men over 75

✍ Hideaki Miyake, Iori Sakai, Ken-ichi Harada, Mototsugu Muramaki, Masato Fujisawa 📂 Article 📅 2012 🏛 Springer Netherlands 🌐 English ⚖ 322 KB

SECOND-LINE CHEMOTHERAPY WITH DOCETAXEL

SECOND-LINE CHEMOTHERAPY WITH DOCETAXEL FOR PROSTATESPECIFIC ANTIGEN (PSA) RELAPSE IN MEN WITH HORMONEREFRACTORY PROSTATE CANCER (HRPC) PREVIOUSLY TREATED WITH DOCETAXEL-BASED CHEMOTHERAPY

✍ C.H. Ohlmann; E. Özgür; S. Wille; U. Engelmann; A. Heidenreich 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Neutropenia as a Potential Pharmacodynam

Neutropenia as a Potential Pharmacodynamic Marker for Docetaxel-Based Chemotherapy in Men With Metastatic Castration-Resistant Prostate Cancer

✍ Gregory R. Pond; William R. Berry; Matthew D. Galsky; Brian A. Wood; Lance Leopo 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 532 KB